ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1786

Vasculitis As Underlying Cause of Death in the United States: 1999 – 2010

Alicia Rodriguez-Pla1, Paul A. Monach2 and Jose Rossello-Urgell3, 1Rheumatology, Boston University, Boston, MA, 2Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, 3Baylor Research Institut, Baylor Institute for Immunology Research, Dallas, TX

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Churg-Strauss syndrome, giant cell arteritis and vasculitis, Takayasu.s arteritis, Wegener's granulomatosis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Current data on mortality rates of primary vasculitis, which were tradionally associated with a dreadful prognosis, are limited. Therefore, we aimed to estimate the mortality rates of the main primary vasculitis disorders using the most current publicly available mortality data in the USA.

  Methods

To obtain mortality rates of vasculitis as the underlying cause of death, we used the CDC Wonder Underlying Cause of Death database and its query system, which contains data from 1999 to 2010. We used the following ICD-10 codes for the queries: D69.0 (Allergic purpura) for Henoch-Schonlein purpura, D89.1 (Cryoglobulinaemia), M30.0 (Polyarteritis nodosa), M30.1 (Polyarteritis with lung involvement [Churg-Strauss]) for eosinophilic granulomatosis with polyangiitis, M30.3 (Mucocutaneous lymph node syndrome [Kawasaki]), M31.0 (Hypersensitivity angiitis) for Goodpasture’s syndrome, M31.3 (Wegener’s granulomatosis) for granulomatosis with polyangiitis (GPA), M31.4 (Aortic arch syndrome [Takayasu]), M31.5 (Giant cell arteritis [GCA] with polymyalgia rheumatica [PMR]) and M31.6 (Other giant cell arteritis) for GCA, M31.7 (Microscopic polyangiitis), and M35.2 (Behcet’s disease). Results were obtained by year, gender, and race. To obtain age-adjusted mortality rates we used year 2000 U.S. standard population. Mortality rates are given as number of deaths per million. Mantel-Haenszel chi-square was used to analyze trends.

 Results 

During the twelve-year period, vasculitis was the underlying cause of death of 7,888 patients. Age-adjusted mortality rate was 2.22 per million (95% CI: 2.17-2.27). There were more deaths in females (4,412) than in males (3,476), but the age-adjusted mortality rate was higher in males than in females (2.28 vs 2.16 per million). Age-adjusted mortality rate was clearly higher in Whites (2.34, 2.28-2.39) than in Black/African American population (1.19, 1.08-1.31). Regarding disease-specific mortality, GPA accounted for 51.2% of all vasculitis deaths. Interestingly, there were no deaths for GCA with PMR. Year 2000 showed the highest mortality (2.58, 2.40-2.77), whereas the lowest level was seen in 2008 (1.79, 1.64-1.94). Since 1999, there has been a significant trend to the decrease (p<0.0001).

 Conclusion

The most current public data indicates that mortality by vasculitis remains very low, which is clearly related to the low incidence of these disorders. Age-adjusted mortality rate was higher in males and in White, which can be explained by the fact that GPA, which is more frequent in males and White, is responsible for half of the overall number of deaths. There is a clear trend to a progressive decrease of the mortality rates by primary vasculitis over the 12-year period of the study. Recent introduction of biological treatments, less toxic therapeutic regimens, such as shortening cyclophosphamide treatment, earlier diagnosis as a result of higher awareness and improved diagnostic tools may have presumably contributed to this decrease in mortality rates. Our findings should be taken with caution until quality studies to determine the reliability of the data about these rare diseases available in national databases are performed.


Disclosure:

A. Rodriguez-Pla,
None;

P. A. Monach,
None;

J. Rossello-Urgell,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vasculitis-as-underlying-cause-of-death-in-the-united-states-1999-2010/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology